1-O-[3-[methyl-[2-[2-[methyl-[3-[4-oxo-4-[[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl]oxy]butanoyl]oxypropyl]amino]ethyldisulfanyl]ethyl]amino]propyl] 4-O-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] butanedioate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-O-[3-[methyl-[2-[2-[methyl-[3-[4-oxo-4-[[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl]oxy]butanoyl]oxypropyl]amino]ethyldisulfanyl]ethyl]amino]propyl] 4-O-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] butanedioate
• 化学式: C₇₈H₁₃₂N₂O₁₀S₂
• 分子量: 1322.05
• InChiKey: MNKAVBAGMNHZIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  22.4
• 重原子数：
  92
• 可旋转键数：
  51
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  181
• 氢给体数：
  0
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  生育酚琥珀酸酯 、 bis[{N-methyl-N-(3-hydroxypropyl)amino}ethyl]disulfide 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 氯仿 为溶剂， 反应 4.0h， 以0.94 g的产率得到1-O-[3-[methyl-[2-[2-[methyl-[3-[4-oxo-4-[[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl]oxy]butanoyl]oxypropyl]amino]ethyldisulfanyl]ethyl]amino]propyl] 4-O-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] butanedioate
  参考文献：
  名称：

  CATIONIC LIPID HAVING IMPROVED INTRACELLULAR KINETICS

  摘要：

  公开号：

  EP2781507B1

文献信息

• CATIONIC LIPID
  申请人：NOF CORPORATION

  公开号：US20180155304A1

  公开（公告）日：2018-06-07

  The present invention aims to provide a cationic lipid that can be used as a nucleic acid delivery carrier, a lipid membrane structure using a cationic lipid, a nucleic acid-introducing agent using a cationic lipid, and a method of achieving nucleic acid introduction by using a nucleic acid-introducing agent containing a cationic lipid. A lipid membrane structure containing a cationic lipid represented by the formula (1) wherein each symbol is as defined in the DESCRIPTION, is superior in the stability in blood and tumor accumulation property. A nucleic acid-introducing agent using the cationic lipid can achieve high nucleic acid delivery efficiency of nucleic acid to be delivered into the cytoplasm.

  本发明旨在提供一种可用作核酸传递载体的阳离子脂质，使用阳离子脂质的脂质膜结构，使用阳离子脂质的核酸引入剂，以及通过使用含有阳离子脂质的核酸引入剂实现核酸引入的方法。含有由式（1）表示的阳离子脂质的脂质膜结构，在血液稳定性和肿瘤聚集性方面具有优越性。使用阳离子脂质的核酸引入剂可以实现将核酸高效传递到细胞质中。
• O/W TYPE EMULSION
  申请人：NOF CORPORATION

  公开号：US20190110986A1

  公开（公告）日：2019-04-18

  The present invention provides an O/W type emulsion having a volume median diameter of not more than 100 nm and containing a compound represented by the formula (1) wherein X a and X b are each independently X 1 , X 2 or a 1,4-piperazinediyl group; s is 1 or 2, R 4 is an alkyl group having 1-6 carbon atoms, n a and n b are each independently 0 or 1, R 1a , R 1b , R 2a and R 2b are each independently an alkylene group having 1-6 carbon atoms, Y a and Y b are each independently an ester bond, or the like, and R 3a and R 3b are each independently a liposoluble vitamin residue or the like.

  本发明提供了一种体积中值直径不超过100纳米的O/W型乳液，其含有由式（1）表示的化合物， 其中X a 和X b 分别独立地为X 1 、X 2 或1,4-哌嗪二基基团； s为1或2， R 4 为具有1-6个碳原子的烷基基团， n a 和n b 分别独立地为0或1， R 1a 、R 1b 、R 2a 和R 2b 分别独立地为具有1-6个碳原子的烷基基团， Y a 和Y b 分别独立地为酯键，或类似物，以及 R 3a 和R 3b 分别独立地为脂溶性维生素残基或类似物。
• Cationic lipid
  申请人：NOF CORPORATION

  公开号：US10385030B2

  公开（公告）日：2019-08-20

  The present invention aims to provide a cationic lipid that can be used as a nucleic acid delivery carrier, a lipid membrane structure using a cationic lipid, a nucleic acid-introducing agent using a cationic lipid, and a method of achieving nucleic acid introduction by using a nucleic acid-introducing agent containing a cationic lipid. A lipid membrane structure containing a cationic lipid represented by the formula (1) wherein each symbol is as defined in the DESCRIPTION, is superior in the stability in blood and tumor accumulation property. A nucleic acid-introducing agent using the cationic lipid can achieve high nucleic acid delivery efficiency of nucleic acid to be delivered into the cytoplasm.

  本发明旨在提供一种可用作核酸递送载体的阳离子脂质、一种使用阳离子脂质的脂膜结构、一种使用阳离子脂质的核酸导入剂，以及一种通过使用含有阳离子脂质的核酸导入剂实现核酸导入的方法。一种含有由式（1）表示的阳离子脂质的脂膜结构 式（1）所代表的阳离子脂质的脂膜结构，其在血液中的稳定性和肿瘤蓄积特性更优越。使用阳离子脂质的核酸导入剂可以实现较高的核酸递送效率，将核酸递送到细胞质中。
• O/W type emulsion
  申请人：NOF CORPORATION

  公开号：US11395798B2

  公开（公告）日：2022-07-26

  The present invention provides an O/W type emulsion having a volume median diameter of not more than 100 nm and containing a compound represented by the formula (1) wherein Xa and Xb are each independently X1, X2 or a 1,4-piperazinediyl group; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a, R1b, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, or the like, and R3a and R3b are each independently a liposoluble vitamin residue or the like.

  本发明提供了一种体积中值直径不超过 100 纳米的 O/W 型乳液，其中含有一种由式（1）表示的化合物 其中 Xa 和 Xb 各自独立地为 X1、X2 或 1,4-哌嗪二基； s 为 1 或 2、 R4 是具有 1-6 个碳原子的烷基、 na 和 nb 分别独立地为 0 或 1、 R1a、R1b、R2a 和 R2b 各自独立地为具有 1-6 个碳原子的亚烷基、 Ya 和 Yb 各自独立地为酯键或类似键，以及 R3a 和 R3b 各自独立地为脂溶性维生素残基或类似物。
• NOVEL TECHNIQUE FOR TREATING CANCER USING STRUCTURALLY-REINFORCED S-TUD
  申请人：National University Corporation Chiba University

  公开号：US20200032262A1

  公开（公告）日：2020-01-30

  Provided is a novel technique for treating cancer using structurally-reinforced S-TuD. Provided are: a composition for the prevention or treatment of tumors, said composition comprising an miRNA inhibitory complex including RNA of analog thereof; and a method for preventing or treating tumors using said composition. The miRNA inhibitory complex preferably includes at least one double-stranded structure and an miRNA-binding sequence. Two strands of the miRNA binding sequence preferably bind individually to two strands on at least one end of the double-stranded structure. According to some of the aspects of the present invention, there is provided a delivery system for delivering such an miRNA inhibitory complex.